|
JP2009524664A
(ja)
*
|
2006-01-25 |
2009-07-02 |
ザ リサーチ ファウンデイション オブ ステイト ユニバーシティー オブ ニューヨーク |
自己／アロ免疫疾患の治療のための抗−ｆｃｒｎ抗体
|
|
US20100166734A1
(en)
*
|
2006-12-20 |
2010-07-01 |
Edward Dolk |
Oral delivery of polypeptides
|
|
US10457719B2
(en)
|
2007-09-18 |
2019-10-29 |
The Jackson Laboratory |
Antibodies and FC fusion protein modifications with enhanced persistence or pharmacokinetic stability in vivo and methods of use thereof
|
|
AU2015200004B2
(en)
*
|
2008-04-25 |
2017-02-16 |
Bioverativ Therapeutics Inc. |
Antibodies against fcrn and use thereof
|
|
BRPI0910622A2
(pt)
*
|
2008-04-25 |
2020-03-10 |
Dyax Corp. |
ANTICORPOS CONTRA FcRn E USOS DOS MESMOS
|
|
KR101722961B1
(ko)
|
2009-02-11 |
2017-04-04 |
알부메딕스 에이/에스 |
알부민 변이체 및 접합체
|
|
US8232067B2
(en)
|
2009-05-29 |
2012-07-31 |
Brigham & Women's Hospital, Inc. |
Disrupting FCRN-albumin interactions
|
|
CA2776241A1
(en)
|
2009-10-30 |
2011-05-05 |
Novozymes Biopharma Dk A/S |
Albumin variants
|
|
US10233228B2
(en)
|
2010-04-09 |
2019-03-19 |
Albumedix Ltd |
Albumin derivatives and variants
|
|
KR102014554B1
(ko)
*
|
2011-06-02 |
2019-08-26 |
다이액스 코포레이션 |
Fc 수용체 결합 단백질
|
|
EP2780364A2
(en)
|
2011-11-18 |
2014-09-24 |
Eleven Biotherapeutics, Inc. |
Proteins with improved half-life and other properties
|
|
WO2013135896A1
(en)
|
2012-03-16 |
2013-09-19 |
Novozymes Biopharma Dk A/S |
Albumin variants
|
|
GB201208370D0
(en)
|
2012-05-14 |
2012-06-27 |
Ucb Pharma Sa |
Antibodies
|
|
MX2015005363A
(es)
|
2012-11-08 |
2015-11-06 |
Novozymes Biopharma Dk As |
Variantes de albumina.
|
|
ES2660912T3
(es)
*
|
2013-03-15 |
2018-03-26 |
Affibody Ab |
Nuevos polipéptidos
|
|
ZA201506407B
(en)
*
|
2013-03-15 |
2018-11-28 |
Affibody Ab |
New polypeptides
|
|
GB201320066D0
(en)
|
2013-11-13 |
2013-12-25 |
Ucb Pharma Sa |
Biological products
|
|
JP6620094B2
(ja)
*
|
2013-11-26 |
2019-12-11 |
ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドＴｈｅ Ｂｒｉｇｈａｍ ａｎｄ Ｗｏｍｅｎ’ｓ Ｈｏｓｐｉｔａｌ， Ｉｎｃ． |
免疫応答を調節するための組成物および方法
|
|
CN112142843B
(zh)
|
2013-12-24 |
2024-10-18 |
阿尔金克斯有限公司 |
FcRn拮抗剂及使用方法
|
|
CA2983794A1
(en)
*
|
2014-04-25 |
2015-10-29 |
The Brigham And Women's Hospital, Inc. |
Methods to manipulate alpha-fetoprotein (afp)
|
|
CA2983796A1
(en)
*
|
2014-04-25 |
2015-10-29 |
The Brigham And Women's Hospital, Inc. |
Compositions and methods for treating subjects with immune-mediated diseases
|
|
US10336825B2
(en)
|
2014-04-30 |
2019-07-02 |
Hanall Biopharma Co., Ltd. |
Antibody binding to FcRn for treating autoimmune diseases
|
|
FI3137504T3
(fi)
|
2014-04-30 |
2023-08-07 |
Hanall Biopharma Co Ltd |
Fcrn:ään sitoutuva vasta-aine autoimmuunisairauksien hoitamista varten
|
|
SI3193930T1
(sl)
|
2014-09-17 |
2019-10-30 |
Affibody Ab |
Novi polipeptidi
|
|
ES2956662T3
(es)
|
2015-05-12 |
2023-12-26 |
Syntimmune Inc |
Anticuerpos anti-FcRn humanizados con afinidad madurada
|
|
GB201508180D0
(en)
|
2015-05-13 |
2015-06-24 |
Ucb Biopharma Sprl |
Antibodies
|
|
WO2017029407A1
(en)
|
2015-08-20 |
2017-02-23 |
Albumedix A/S |
Albumin variants and conjugates
|
|
CN106957365B
(zh)
|
2016-01-11 |
2021-03-16 |
上海交通大学 |
一种单克隆抗体FnAb8及其应用
|
|
GB201618424D0
(en)
*
|
2016-11-01 |
2016-12-14 |
Argenix Bvba |
Treatment of antibody mediated disease
|
|
US12240875B2
(en)
|
2017-12-08 |
2025-03-04 |
argenx BV |
Use of FCRN antagonists for treatment of generalized myasthenia gravis
|
|
CA3101462A1
(en)
|
2018-06-08 |
2019-12-12 |
Argenx Bvba |
Compositions and methods for treating immune thrombocytopenia
|
|
MA53903A
(fr)
|
2018-10-16 |
2021-08-25 |
UCB Biopharma SRL |
Méthode de traitement de la myasthénie grave
|
|
CN114126647A
(zh)
|
2019-06-07 |
2022-03-01 |
阿尔金克斯有限公司 |
适用于皮下施用的FcRn抑制剂的药物制剂
|
|
BR112022013554A2
(pt)
|
2020-01-08 |
2022-09-06 |
argenx BV |
Métodos para tratar distúrbios do pênfigo
|
|
US20230220069A1
(en)
*
|
2020-06-17 |
2023-07-13 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for treatment of gene therapy patients
|
|
US20250136699A1
(en)
*
|
2021-08-13 |
2025-05-01 |
Jiangsu Biojetay Biotechnology Co., Ltd. |
Antibodies specifically recognizing fcrn and uses thereof
|
|
EP4508074A1
(en)
*
|
2022-04-13 |
2025-02-19 |
Ose Immunotherapeutics |
New class of molecules for selective clearance of antibody
|
|
AU2023281650A1
(en)
|
2022-05-30 |
2024-10-17 |
Hanall Biopharma Co., Ltd. |
Anti-fcrn antibody or antigen binding fragment thereof with improved stability
|
|
CA3258000A1
(en)
|
2022-06-15 |
2023-12-21 |
argenx BV |
FCRN/ANTIGEN BINDING MOLECULES AND METHODS OF USE
|